The major advantage of immunotherapy (IT) have been demonstrated recently and making IT an advanced cancer treatment. As a cell immunotherapy, the encapsulated approach provides several advantages over the direct-injection one. Here we present a novel substrate of microtube array membrane (MTAM) for the encapsulation of the functional cell, in this case, a hybridoma cell which secrets necessary protein, a monoclonal antibody (mAb), to improve the immune system of cancer patient for treating cancer. MTAM, with unique structural characteristics, such as larger surface area per volume, thinner and nano-porous tube wall, and one-by-one connected array formation, provides an excellent environment for the major survival of encapsulated cell with ample of nutrient and the release of the secreted protein when necessary. In long run, we believe the proposed EC/MTAM can be a safe, effective approach for cancer immunotherapy. This two-year project will be begin with the in vitro investigation of the MTAM-encapsulated hybridoma cell, such as the encapsulation procedure and parameters, subsequently the resulting cell viability and functionality. The high cell viability and its designed cell function of enhancing immune-system via specific markers will be demonstrated. The second part of project will be subjected this EC/MTAM under in vivo model in which both the EC/MTAM and cancer cell will be implanted subcutaneously in model for its treatment efficacy evaluation.
|Effective start/end date||8/1/17 → 7/31/18|
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.